Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2155
Abstract: Maribavir, an orally bioavailable antiviral, has shown superior activity against posttransplant cytomegalovirus infection compared with conventional antivirals. It is primarily metabolized in the liver. This open‐label, single‐center study evaluated the effect of hepatic impairment on… read more here.
Keywords: participants moderate; hepatic impairment; maribavir; impairment ... See more keywords
Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
Sign Up to like & getrecommendations! Published in 2021 at "Antiviral research"
DOI: 10.1016/j.antiviral.2021.105139
Abstract: Because ganciclovir resistance mutations in the cytomegalovirus UL97 gene most commonly occur at codons 460, 520 and 590-607, diagnostic genotyping for drug resistance has often omitted the analysis of codons below 440. However, the UL97… read more here.
Keywords: binding region; maribavir; ganciclovir maribavir; atp binding ... See more keywords
Summary of Maribavir (SHP620) Drug–Drug Interactions Based on Accumulated Clinical and Nonclinical Data
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.600
Abstract: Introduction Maribavir, a potent and orally bioavailable antiviral, is being evaluated in Phase 3 trials for the treatment of cytomegalovirus (CMV) infections in transplant patients. Often numerous concomitant medications are administered to these patients to… read more here.
Keywords: drug interactions; drug; summary maribavir; maribavir ... See more keywords
Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac686
Abstract: TO THE EDITOR—Cytomegalovirus (CMV) infection remains a frequent cause of morbidity and mortality among stem-cell and solid organ transplant recipients, with devastating complications including graft failure and death [1, 2]. Limitations of existing anti-CMV agents… read more here.
Keywords: maribavir cytomegalovirus; maribavir; cmv infection; treatment ... See more keywords
Elucidation of Metabolic and Disposition Pathways for Maribavir in Nonhuman Primates through Mass Balance and Semi–Physiologically Based Modeling Approaches
Sign Up to like & getrecommendations! Published in 2021 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.121.000493
Abstract: Maribavir is in phase 3 clinical development for treatment of cytomegalovirus infection/disease in transplant recipients. Previous research conducted using only intact cynomolgus monkeys indicated biliary secretion as the primary elimination pathway for maribavir and that… read more here.
Keywords: maribavir; mass balance; semi; physiologically based ... See more keywords